Bio-Techne to Present at Upcoming Investor Conferences

Bio-Techne to Present at Upcoming Investor Conferences

Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences:

2025 Wells Fargo Healthcare Conference
September 3, 2025
10:15 AM EDT

Baird 2025 Global Healthcare Conference
September 9, 2025
9:05 AM EDT

Morgan Stanley 23 rd Annual Global Healthcare Conference
September 10, 2025
10:45 AM EDT

A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar .

About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: LinkedIn , X or YouTube .

Contact: David Clair , Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/bio-techne-to-present-at-upcoming-investor-conferences-302539292.html

SOURCE Bio-Techne Corporation

News Provided by PR Newswire via QuoteMedia

TECH:US
The Conversation (0)
Bio-Techne Corp

Bio-Techne Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Latest Press Releases

Related News

×